Aligos Therapeutics, Inc. Capital Expenditures
Aligos Therapeutics, Inc. (ALGS) reported Capital Expenditures of $130.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-03-10
- Aligos Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $7.00K, a 98.64% decline year-over-year.
- Aligos Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2022-12-31 was $91.00K, a 72.92% decline year-over-year.
- Aligos Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2022-09-30 was $3.00K, a 96.91% decline year-over-year.
- Aligos Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2022-06-30 was $334.00K, a 119.74% increase year-over-year.
- Aligos Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $130.00K, a 584.21% increase from fiscal 2023.
- Aligos Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $19.00K, a 97.99% decline from fiscal 2022.
- Aligos Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $943.00K, a 5.72% increase from fiscal 2021.
- Aligos Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $892.00K, a 56.78% decline from fiscal 2020.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2024-12-31 | $130.00K 10-K · filed 2025-03-10 | |||
| 2023-12-31 | $19.00K 10-K · filed 2025-03-10 | |||
| 2023-03-31 | $7.00K 10-Q · filed 2023-05-04 | $98.00K derived: sum of 2 quarters · filed 2024-03-12 | $101.00K derived: sum of 3 quarters · filed 2024-03-12 | $435.00K derived: sum of 4 quarters · filed 2024-03-12 |
| 2022-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $94.00K derived: sum of 2 quarters · filed 2024-03-12 | $428.00K derived: sum of 3 quarters · filed 2024-03-12 | $943.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $337.00K derived: sum of 2 quarters · filed 2022-11-02 | $852.00K 10-Q · filed 2022-11-02 | $1.19M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $334.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $849.00K 10-Q · filed 2022-08-04 | $1.19M derived: sum of 3 quarters · filed 2023-05-04 | $1.28M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $515.00K 10-Q · filed 2023-05-04 | $851.00K derived: sum of 2 quarters · filed 2023-05-04 | $948.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.10M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $336.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $433.00K derived: sum of 2 quarters · filed 2023-03-09 | $585.00K derived: sum of 3 quarters · filed 2023-03-09 | $892.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $249.00K derived: sum of 2 quarters · filed 2022-11-02 | $556.00K 10-Q · filed 2022-11-02 | $617.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $152.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $459.00K 10-Q · filed 2022-08-04 | $520.00K derived: sum of 3 quarters · filed 2022-08-04 | $864.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $307.00K 10-Q · filed 2022-05-04 | $368.00K derived: sum of 2 quarters · filed 2022-05-04 | $712.00K derived: sum of 3 quarters · filed 2022-05-04 | $1.28M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $405.00K derived: sum of 2 quarters · filed 2022-03-10 | $974.00K derived: sum of 3 quarters · filed 2022-03-10 | $2.06M 10-K · filed 2022-03-10 |
| 2020-09-30 | $344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $913.00K derived: sum of 2 quarters · filed 2021-11-04 | $2.00M 10-Q · filed 2021-11-04 | $2.72M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $569.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.66M 10-Q · filed 2021-08-05 | $2.38M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $1.09M 10-Q · filed 2021-05-10 | $1.81M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $721.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $2.79M 10-K · filed 2021-03-23 | ||
| 2019-09-30 | $2.06M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |